If marijuana is rescheduled from a Schedule 1 to a Schedule 3 substance, it won’t change the laws regulating cannabis research.
But the demand for research of the plant and cannabis for research purposes will grow, legal experts and marijuana producers say.
ADVERTISEMENT
So far, the U.S. Drug Enforcement Administration has approved eight companies to provide researchers with marijuana products for studies and 600-plus researchers to conduct that work.
“I believe demand is going to skyrocket,” Richard Shain, CEO of Maridose, a DEA-licensed bulk manufacturer of cannabis, said in an interview with MJBizDaily.
Shain said he believes the medical community’s interest in marijuana research will grow as a result of rescheduling, and more researchers will seek approval to conduct studies with patients.
Preparing for
Read full article on Marijuana Business Daily
